Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gross Profit: 2013-2024

Historic Gross Profit for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Dec 2024 value amounting to -$1.9 million.

  • Rocket Pharmaceuticals' Gross Profit fell 0.42% to -$473,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 0.42%. This contributed to the annual value of -$1.9 million for FY2024, which is 0.59% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Gross Profit stood at -$1.9 million for FY2024, which was down 0.59% from -$1.9 million recorded in FY2023.
  • Rocket Pharmaceuticals' Gross Profit's 5-year high stood at -$1.9 million during FY2022, with a 5-year trough of -$7.0 million in FY2020.
  • Over the past 3 years, Rocket Pharmaceuticals' median Gross Profit value was -$1.9 million (recorded in 2023), while the average stood at -$1.9 million.
  • In the last 5 years, Rocket Pharmaceuticals' Gross Profit dropped by 16.94% in 2020 and then soared by 57.27% in 2021.
  • Rocket Pharmaceuticals' Gross Profit (Yearly) stood at -$7.0 million in 2020, then skyrocketed by 57.27% to -$3.0 million in 2021, then spiked by 37.45% to -$1.9 million in 2022, then declined by 0.70% to -$1.9 million in 2023, then fell by 0.59% to -$1.9 million in 2024.